Innovation for Health - 13 February 2020
Contact Global Investor Forum I4H Bootcamp
LinkedIn
Twitter
Facebook
Innovation for Health - Shaping the future of healthcare

Jan van de Winkel

President & CEO, Genmab

Jan van de Winkel is President and Chief Executive Officer of Genmab, which he co-founded in February 1999. Genmab is a leading international biotechnology company focused on developing innovative antibody therapeutics for cancer.

Dr. van de Winkel has overseen the creation and development of a number of human antibodies for the treatment of cancer and other diseases.
Genmab has two approved and marketed drugs, DARZALEX® (daratumumab) for the treatment of multiple myeloma, and Arzerra® (ofatumumab) for the treatment of chronic lymphocytic leukemia. Daratumumab is in clinical development for additional multiple myeloma indications, NKT-cell lymphoma, and amyloidosis. A subcutaneous formulation of ofatumumab is in Phase III development for relapsing multiple sclerosis. Genmab has a broad pre-clinical and clinical product pipeline. Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, the HexaBody® platform which creates effector function enhanced antibodies, the HexElect® platform, which combines two co-dependently acting HexaBody molecules to introduce selectivity while maximizing therapeutic potency, and the DuoHexaBody® platform, which enhances the potency of bispecific antibodies through hexamerization. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies.

Dr. van de Winkel has over 30 years of experience in the therapeutic antibody field and served as Vice President and Scientific Director of Medarex Europe prior to Genmab. He is the author of over 300 scientific publications and has been responsible for over 100 patents and patent applications. Dr. van de Winkel holds a professorship of Immunotherapy at Utrecht University. He is chairman of the board of directors of Hookipa Biotech AG, member of the board of directors of LEO Pharma and Celdara Medical, the scientific advisory board of Thuja Capital Healthcare Fund and the advisory board of Capricorn Health-tech Fund.
Marcel Levi
University College London Hospitals
Jan van de Winkel
Genmab
Annemarie Jorritsma
NVP
Ton Rijnders
Lygature
Koen Kas
UGhent & HealthSkouts
Rajiv Vaid Basaiawmoit
Aarhus University & Biosymfonix

Claudia Rijcken
pharmi

Inge Huitinga
Netherlands Brain Bank
Wiro Niessen
Erasmus MC, TU Delft & Quantib
Els Beirnaert
Aelin Therapeutics
Joep Muijrers
PureTech Health
Koenraad Wiedhaup
McKinsey & Company
Esther Talboom-Kamp
Saltro Diagnostics
Elise Meijer
Antwerp Management School & Accenture Strategy
Carine van den Brink
Axon Lawyers
Tim Knotnerus
AgomAb Therapeutics
Sjaak Vink
TheSocialMedwork
Hans Schikan
Topsector Life Sciences & Health
Thijn Brummelkamp
Scenic Biotech
Nadine Rouleaux
Maastricht University
Charlotte Kluit
MSD
Dharminder Chahal
SkylineDx, Van Herk Investments, Swanbridge

Marianne van der Steen
RegMedXB & Maastricht University

Jan de Kerpel
Kempen & Co
Wim Van Hecke
icoMetrix
Wiesje van der Flier 
Alzheimercentrum Amsterdam
Niels Prins
Marco Blom
Alzheimer Nederland
Edwin Moses
Achilles Therapeutics & Evox Therapeutics
Carl Moons
Health Innovation Initiative Holland
Jan Kimpen
Philips
Linda van de Burgwal 
Vrije Universiteit Amsterdam
Onno van de Stolpe
Galapagos
Ton van der Steen
Erasmus MC, Medical Delta & STW
Sponsors & Partners 2020
Host sponsor
Erasmus MC
Host sponsor
Gemeente Rotterdam
Host sponsor
Life Sciences & Health 010
Platinum sponsor
Platinum sponsor
Gold sponsor
Silver sponsor
Silver sponsor
Programme Sponsor AI
Award sponsor
AXON Lawyers
Media sponsor
Powered by
Hyphen Projects
© 2019 Innovation for Health
Hyphen Projects uses cookies to remember certain preferences.